Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Net Cash Flow for 8 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 2867.33% year-over-year to -$4.5 million, compared with a TTM value of -$61.1 million through Dec 2025, down 11.17%, and an annual FY2025 reading of -$61.1 million, down 11.17% over the prior year.
  • Net Cash Flow was -$4.5 million for Q4 2025 at Arcturus Therapeutics Holdings, up from -$16.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $154.2 million in Q4 2022 and bottomed at -$63.9 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$11.5 million, with a median of -$20.1 million recorded in 2023.
  • The sharpest move saw Net Cash Flow soared 455.47% in 2022, then plummeted 2867.33% in 2025.
  • Year by year, Net Cash Flow stood at -$43.4 million in 2021, then skyrocketed by 455.47% to $154.2 million in 2022, then tumbled by 113.07% to -$20.2 million in 2023, then skyrocketed by 99.26% to -$150000.0 in 2024, then tumbled by 2867.33% to -$4.5 million in 2025.
  • Business Quant data shows Net Cash Flow for ARCT at -$4.5 million in Q4 2025, -$16.1 million in Q3 2025, and -$20.5 million in Q2 2025.